Company
Enodia Therapeutics
Developing small-molecule therapies that selectively degrade disease-driving proteins upstream before damage occurs, beginning with immuno-inflammatory disorders.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- Paris, France
- Founded
- 2025
- Legal name
- Enodia Therapeutics
Claim, correct or request removal
Record updated 28 September 2026
About
To develop best-in-class small molecules, targeting the Sec61 translocon, to degrade single or multiple disease-related proteins at the point of synthesis, before they can exert pathological effects.
Funding snapshot
- Latest round
- Seed2026-01-08
Funding rounds
- Seed
- 2026-01-08
Loading relationship preview